Table 2 Baseline characteristics of patients with unstable Angina pectoris (n = 174)

TF Activity, (pmol)

7.39 ± 0.60

53.9 ± 2.76

<0.001

TF Activity + anti TFPI, (pmol)

41.36 ± 1.92

66.17 ± 2.38

<0.001

Demographics

   Median age, years

66.6 ± 1.05

67.2 ± 1.36

0.79

   Male sex

76 (71.7%)

37 (54.4%)

0.88

   Number of CV death (n)

10 (9.4%)

5 (7.4%)

   Time to death (days)

655.47 ± 123.49

642.78 ± 137.90

0.93

   Days of follow up (days)

1414.48 ± 11.24

1443.75 ± 8.39

0.13

Previous medical history

   Myocardial infarction

35 (33.0%)

21 (30.9%)

0.74

   ACVB

13 (12.3%)

7 (10.3%)

0.69

Cardiovascular risk factors

   Arterial hypertension

91 (85.9%)

56 (82.4%)

0.54

   Diabetes mellitus

28 (26.4%)

28 (41.2%)

0.07

   Hypercholesterolemia

69 (65.1%)

40 (58.8%)

0.35

   Current smoker

51 (48.1%)

30 (44.1%)

0.50

Biochemical markers

   Peak creatine kinase, U/l

92.7 ± 5.39

188.2 ± 15.39

0.56

   C-reactive protein, mg/dl

22.9 ± 4.00

24.8 ± 4.37

0.19

   NT-pro-BNP, pg/ml

2321.24 ± 490.50

2176.1 ± 306.79

0.13

Clinical data

   Prehospital CPR

1 (0.9%)

1 (1.5%)

0.75

   Cardiogenic shock

2 (1.9%)

0 (0.0%)

0.26

   Killip's class

I

103 (97.2%)

64 (94.1%)

0.32

II

2 (1.9%)

1 (1.5%)

0.84

III

0 (0.0%)

2 (2.9%)

0.08

IV

1 (0.9%)

1 (1.5.%)

0.75

Angiographic data

   Left ventricular function

52.6 ± 1.38

51.5 ± 1.77

0.67

   Target vessel

LAD

44 (41.5%)

33 (48.5%)

0.27

RCA

33 (31.1%)

24 (35.3%)

0.20

LCx

29 (27.4%)

11 (16.8%)

0.14

   Extent of coronary artery

   Disease

1-vessel-disease

21 (19.8%)

13 (19.1%)

0.90

2-vessel-disease

32 (30.2%)

21 (30.9%)

0.76

3-vessel-disease

53 (50.0%)

34 (50.0%)

0.85

   Medication on admission

Aspirin

106 (100%)

68 (100.0%)

1.00

Heparin

63 (63.4%)

38 (55.9%)

0.79

Clopidogrel

91 (85.8%)

49 (72.1%)

0.54

Beta-Blockers

62 (58.5%)

38 (55.8%)

0.82

ACE-Inhibitors

53 (50.0%)

29 (42.7%)

0.34

Statins

44 (41.5%)

24 (35.3%)

0.46